Potential Impact of a 9-valent HPV Vaccine in HPV-Related Cervical Disease in 4 Emerging Countries (Brazil, Mexico, India and China)
This article, published in Cancer Epidemiology, reports on a study that estimated the potential impact of an investigational 9-valent human papillomavirus (HPV) vaccine (HPVs 6/11/16/18/31/33/45/52/58) on HPV-related cervical disease in Brazil, Mexico, India, and China, in order to help to formulate recommendations on cervical cancer prevention and control. The authors found that the addition of HPVs 31/33/45/52/58 to the HPV types included in current vaccines could increase the invasive cervical cancer preventable fraction in a range of 12 to 19 percent across the four countries. Therefore, assuming the same degree of efficacy of current vaccines, they conclude that the implementation of the 9-valent HPV vaccine in Brazil, Mexico, India, and China would substantially reduce cervical cancer burden.
Author: Serrano B, Alemany L, de Ruiz PA, et al.
» Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Serrano B, Alemany L, de Ruiz PA, et al. Potential Impact of a 9-valent HPV Vaccine in HPV-Related Cervical Disease in 4 Emerging Countries (Brazil, Mexico, India and China). Cancer Epidemiology. 2014;38(6):748-756.
Resource types: Peer-reviewed journal
Diseases/vaccines: Human papillomavirus (HPV)